Patents by Inventor Dianwu Guo
Dianwu Guo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220000840Abstract: The invention provides a pharmaceutical composition for injection comprising a NL-101 type compound and a preparation method thereof. The composition uses the NL-101 type compound as an active pharmaceutical ingredient, and the stability of the NL-101 type compound is improved by adding a chloride-containing stabilizing agent or using a co-solvent containing hydrochloric acid, so that the formulation can be stably produced and meet the requirements for clinical safe use.Type: ApplicationFiled: September 16, 2021Publication date: January 6, 2022Inventors: Weiliang XU, Jingya FANG, Feiyu FENG, Lan YANG, Dianwu GUO, Fujiang ZHU, Qiufu GE
-
Publication number: 20180311215Abstract: The invention provides a pharmaceutical composition for injection comprising a NL-101 type compound and a preparation method thereof. The composition uses the NL-101 type compound as an active pharmaceutical ingredient, and the stability of the NL-101 type compound is improved by adding a chloride-containing stabilizing agent or using a co-solvent containing hydrochloric acid, so that the formulation can be stably produced and meet the requirements for clinical safe use.Type: ApplicationFiled: October 20, 2016Publication date: November 1, 2018Applicant: Hangzhou TINO Pharma Co., Ltd.Inventors: Weiliang XU, Jingya FANG, Feiyu FENG, Lan YANG, Dianwu GUO, Fujiang ZHU, Qiufu GE
-
Patent number: 9499530Abstract: A class of quinazoline derivatives or pharmaceutically acceptable salts or solvates thereof with novel structures is provided; meanwhile, a pharmaceutical composition comprising a pharmaceutically effective amount of said quinazoline derivatives or pharmaceutically acceptable salts or solvates thereof, and pharmaceutically acceptable excipients or additives is also provided. By modifying and transforming the quinazoline and screening of the transformed compounds on the activity of tyrosine kinase inhibition, most of the compounds have been found to possess inhibitory activity against one or several of EGFR, VEGFR-2, c-erbB-2, c-erbB-4, c-met, tie-2, PDGFR, c-src, lck, Zap70 and fyn kinases. The present invention has the advantages of reasonable design, broad source of and easy access to the raw materials, simple and easy operation of the preparation methods, mild reaction conditions, high yield of the products and being beneficial for industrial-scale production.Type: GrantFiled: July 21, 2012Date of Patent: November 22, 2016Assignees: HANGZHOU MINSHENG INSTITUTES FOR PHARMA RESEARCH, HANGZHOU MINSHENG PHARMACEUTICAL CO. LTDInventors: Shulong Wang, Jian Cai, Qiufu Ge, Dianwu Guo, Lan Yang, Binnan Huang, Zhenhua Liu, Zhonghua Peng, Ximing Shen, Feiyu Feng
-
Patent number: 9376395Abstract: The present invention is directed to pharmaceutical compositions comprising: (a) a cyclopolysaccharide and (b) a compound of Formula (I) or its pharmaceutical acceptable salt: wherein X1, X2, Q, Z, and m are defined herein. Also disclosed is a method for treating a neoplastic disease or an immune disease with these compositions.Type: GrantFiled: September 14, 2012Date of Patent: June 28, 2016Assignee: Purdue Pharmaceuticals Products L.P.Inventors: Yu Chen, Lan Yang, Feiyu Feng, Qiufu Ge, Dianwu Guo, Yi Chen
-
Publication number: 20150183747Abstract: The present invention is directed to pharmaceutical compositions comprising: (a) a cyclopolysaccharide and (b) a compound of Formula (I) or its pharmaceutical acceptable salt: wherein X1, X2, Q, Z, and m are defined herein. Also disclosed is a method for treating a neoplastic disease or an immune disease with these compositions.Type: ApplicationFiled: September 14, 2012Publication date: July 2, 2015Applicant: Purdue Pharmaceutical Products L.P.Inventors: Yu Chen, Lan Yang, Feiyu Feng, Qiufu Ge, Dianwu Guo, Yi Chen
-
Publication number: 20150080392Abstract: A class of quinazoline derivatives or pharmaceutically acceptable salts or solvates thereof with novel structures is provided; meanwhile, a pharmaceutical composition comprising a pharmaceutically effective amount of said quinazoline derivatives or pharmaceutically acceptable salts or solvates thereof, and pharmaceutically acceptable excipients or additives is also provided. By modifying and transforming the quinazoline and screening of the transformed compounds on the activity of tyrosine kinase inhibition, most of the compounds have been found to possess inhibitory activity against one or several of EGFR, VEGFR-2, c-erbB-2, c-erbB-4, c-met, tie-2, PDGFR, c-src, lck, Zap70 and fyn kinases. The present invention has the advantages of reasonable design, broad source of and easy access to the raw materials, simple and easy operation of the preparation methods, mild reaction conditions, high yield of the products and being beneficial for industrial-scale production.Type: ApplicationFiled: July 21, 2012Publication date: March 19, 2015Applicants: HANGZHOU MINSHENG PHARMACEUTICAL CO. LTD, HANGZHOU MINSHENG INSTITUTES FOR PHARMA RESEARCHInventors: Shulong Wang, Jian Cai, Qiufu Ge, Dianwu Guo, Lan Yang, Binnan Huang, Zhenhua Liu, Zhonghua Peng, Ximing Shen, Feiyu Feng
-
Patent number: 8628806Abstract: The present invention provides a hypolipidemic composition comprising peony extract and Codonopsis extract, or comprising water coextract of peony and Codonopsis, the weight ratio of the peony extract to Codonopsis extract in the composition is between 0.5 and 19:1. The advantages of the hypolipidemic composition are: substantially decreasing triglyceride and cholesterol, while increasing high density lipoprotein. It suggested of a favourable prospect of application.Type: GrantFiled: September 26, 2007Date of Patent: January 14, 2014Assignee: Hangzhou Minsheng Pharmaceutical Co., Ltd.Inventors: Like Tang, Dianwu Guo, Chunxia Wu, Kai Tang, Tianjia Xu
-
Patent number: 7700584Abstract: The present invention provides curcumol derivatives of the following formula (I) or pharmaceutical acceptable salts thereof: wherein, Y is selected from the group consisting of ?CHR2, —CH2R2, ?O, ?—OH or —OR1;R1 is selected from H, R, RCO or HO3S; and R is selected from the group consisting of H; saturated or unsaturated linear C1-10 hydrocarbon group and the like; R2 is selected from the group consisting of F; Cl; Br; I; H; —OH; —OR; —HSO3 and the like; with the proviso that both R1 and R2 are not H. The present invention also provides anti-tumor or antiviral pharmaceutical compositions comprising said derivatives or pharmaceutical acceptable salts thereof. The present invention further provides the use of said derivatives or pharmaceutical acceptable salts thereof in the preparation of a medicament for prophylaxis and/or treatment tumor or an antiviral medicament.Type: GrantFiled: May 26, 2005Date of Patent: April 20, 2010Assignee: Hangzhou Minsheng Pharmaceuticals Co., Ltd.Inventors: Shulong Wang, Dianwu Guo, Zhaoke Meng
-
Publication number: 20100021575Abstract: The present invention provides a hypolipidemic composition comprising peony extract and Codonopsis extract, or comprising water coextract of peony and Codonopsis, the weight ratio of the peony extract to Codonopsis extract in the composition is between 0.5 and 19:1. The advantages of the hypolipidemic composition are: substantially decreasing triglyceride and cholesterol, while increasing high density lipoprotein. It suggested of a favourable prospect of application.Type: ApplicationFiled: September 26, 2007Publication date: January 28, 2010Inventors: Like Tang, Dianwu Guo, Chunxia Wu, Kai Tang, Tianjia Xu
-
Patent number: 7435838Abstract: The present invention relates to the diol intermediate of citalopram useful for treatment of depression, which is the crystal of free base of 3-hydroxylmethyl-4-[1-(4-fluorophenyl)-1-hydroxyl-4-(dimethylamino)]butylbenzonitrile and the method of crystallization thereof. The present invention has disclosed the method to prepare pure citalopram and its purified salts through crystallization of the described base; the optical resolution method of citalopram diol intermediate, the method to prepare S-citalopram and its purified salts by crystals mentioned above. The present invention has also disclosed the method to prepare citalopram and its purified salts, S-citalopram and its purified salts, as well as pharmaceutical formulation thereof obtained. Using methods of the present invention, the quality and yield of the product can be significantly improved, and the production cost of the medicinal material can be reduced.Type: GrantFiled: December 6, 2004Date of Patent: October 14, 2008Assignee: Hangzhou Minsheng Pharmaceutical Co. Ltd.Inventors: Runan Mei, Dianwu Guo, Shulong Wang
-
Publication number: 20070191360Abstract: The present invention provides curcumol derivatives of the following formula (I) or pharmaceutical acceptable salts thereof: wherein, Y is selected from the group consisting of ?CHR2, —CH2R2, ?O, ?—OH or —OR1;R1 is selected from H, R, RCO or HO3S; and R is selected from the group consisting of H; saturated or unsaturated linear C1-10 hydrocarbon group and the like; R2 is selected from the group consisting of F; Cl; Br; I; H; —OH; —OR; —HSO3 and the like; with the proviso that both R1 and R2 are not H. The present invention also provides anti-tumor or antiviral pharmaceutical compositions comprising said derivatives or pharmaceutical acceptable salts thereof. The present invention further provides the use of said derivatives or pharmeceutical acceptable salts thereof in the preparation of a medicament for prophylaxis and/or treatment tumor or an antiviral medicament.Type: ApplicationFiled: May 26, 2005Publication date: August 16, 2007Applicant: HANGZHOU MINSHENG PHARMACEUTICALS CO., LTD.Inventors: Shulong Wang, Dianwu Guo, Zhaoke Meng
-
Publication number: 20070117992Abstract: The present invention relates to the diol intermediate of citalopram useful for treatment of depression, that is to say, the crystal of free alkali of 3-hydroxylmethyl-4-[1-(4-fluorophenyl)-1-hydroxyl-4-(dimethylamino)] butylbenzonitrile and the method of crystallization thereof. The present invention has disclosed the method to prepare pure citalopram and its purified salts through crystallization of the described alkali;the optical resolution method of citalopram diol intermediate, the method to prepare S-citalopram and its purified salts by crystals mentioned above. The present invention has also disclosed the method to prepare citalopram and its purified salts, S-citalopram and its purified salts, as well as pharmaceutical formulation thereof obtained. Using methods of the present invention, the quality and yield of the product can be signally improved, and the production cost of the medicinal material can be decreased.Type: ApplicationFiled: December 6, 2004Publication date: May 24, 2007Inventors: Runan Mei, Dianwu Guo, Shulong Wang